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doi:10.1016/j.jmii.2011.09.024Background/Purpose: To investigate the clinical manifestations, disease activity and prognosis
in different types of vasculitis.
Methods: The charts of pediatric patients with vasculitis diagnosed from December 1997 to
December 2007 were retrospectively reviewed. The first clinical manifestations and laboratory
results were recorded at the time of diagnosis, and outcome evaluations with history of flare-
ups were analyzed.
Results: A total of 508 vasculitis patients were included in this study, of whom 124 had Henoche
Scho¨nlein purpura (HSP), and 351 had Kawasaki disease (KD). Hematuria was observed in 79% of
recurrent HSP patients at the time of diagnosis, and was associated with an increased risk of
relapse (pZ 0.000). In Kawasaki disease, the clinical symptoms with erythematous changes in
Bacille Calmette-Gue´rin scars and coronary artery dilatation were more prominent in patients
younger than 1 year old, and lymphadenopathy was more common in patients older than 1 year
old (p Z 0.001). The risk of coronary dilatation was significant in the patients with an initial
presentation of thrombocytosis, and greater in patients younger than 1 year old
(p Z 0.027). Thrombocytopenia was more prominent in vasculitis-associated autoimmune
diseases. Marked lymphocytosis with increased C-reactive protein levels was significantly
noted in urticarial vasculitis patients compared with HSP patients in multivariate logistic
regression analysis.of Pediatrics, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, Taiwan,
tw (B.-L. Chiang).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Childhood vasculitis 23Conclusion: Vasculitis disease activity and prognosis were associated with initial laboratory
results and clinical manifestations. Further large-scale clinical trials are warranted to validate
these findings.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Vasculitis in childhood is a result of causes ranging from
idiopathic conditions with primary vessel inflammation to
syndromes after exposure to recognized antigenic triggers
such as infectious agents and drugs causing hypersensitivity
reactions. Vasculitis is also a component of many autoim-
mune diseases.
Childhood vasculitides are complex, multisystemic dis-
eases,,and include many different types of disease.
Vasculitis is generally classified as primary, secondary or
incidental. It is an inflammatory process mediating
destruction of the vessel walls by unknown causes, leading
to hemorrhage, ischemia and/or infarction.1,2 Primary
vasculitis syndromes include systemic and cutaneous vari-
ants, such as idiopathic cutaneous leukocytoclastic vascu-
litis, HenocheScho¨nlein purpura (HSP), Wegener’s
granulomatosis (WG), and ChurgeStrauss syndrome (CSS).
Secondary vasculitis syndromes include vasculitis associ-
ated with autoimmune diseases, infections, drug eruptions,
malignancies and others involved in small-vessel vasculit-
ides. Incidental vasculitis represents a localized histological
finding that is the consequence of another pathology, such
as traumatic ulceration or diffuse neutrophilic infiltration1,2
(Table 1).
Takayasu arteritis (TA) is the third-most common form of
childhood vasculitis worldwide after HSP and Kawasaki
disease, with a 2.5:1 female:male ratio. About one-third of
cases have an onset before 20 years of age, and symptoms
usually appear after 10 years of age, although children as
young as 8 months have been affected.
Kawasaki disease (KD) is an acute febrile vasculitis of
childhood. Approximately 20% of untreated patients develop
coronary artery abnormalities. The cause of the illness
remains unknown, but epidemiological and clinical features
strongly support an infectious origin. The illness occurs
predominantly in young children, and 80% of patients are
less than 5 years of age. Kawasaki disease causes severe
vasculitis of all blood vessels, but predominantly affects the
medium-sized arteries. Prolonged fever is prognostic for the
development of coronary artery disease, and perineal
desquamation has also been noted in the acute phase.
Heno¨ch-Schonlein purpura (HSP), also known as
anaphylactoid purpura, is a common vasculitis of small
vessels with cutaneous and systemic complications. It is the
most common cause of nonthrombocytopenic purpura in
children. The etiology is unknown, but HSP often follows an
upper respiratory tract infection. HSP occurs more
frequently in children, with most cases occurring between 2
and 8 years of age, and most frequently in the winter
months. The overall incidence is estimated to be
14/100,000population, and males are affected twice asfrequently as females. Arthritis, present in more than two-
thirds of children with HSP, is usually localized to the
knees and ankles, and appears to be concomitant with
edema. Edema and damage to the vasculature of the
gastrointestinal tract may also lead to intermittent
abdominal pain that is often colicky in nature. Renal
involvement occurs in 25e50% of children and manifests
with hematuria, proteinuria, or both. The major compli-
cations of HSP are renal involvement, including nephrotic
syndrome, and bowel perforation. One population-based
study indicated that 4% of patients with HSP develop
persistent renal disease and less than 0.1% develop serious
renal disease.
Wegener’s granulomatosis (WG) is a necrotizing granu-
lomatous small-vessel vasculitis that occurs at all ages and
often involves the upper airways, lower respiratory tract
and kidneys. Although most cases occur in adults, children
can develop WG with a mean age at diagnosis of 6 years,
but it may present as early as 2 weeks of age. There is
a female predominance of 3:1.
ChurgeStrauss syndrome is a vasculitis that can cause
chronic sinus lesions. Diagnostic criteria include a history of
asthma, circulating eosinophilia and an eosinophilic cuta-
neous vasculitis that often involves lymphadenopathy.
There is little information showing an association of
disease activity and prognosis with initial laboratory results
and clinical symptoms. In this study, we aimed to investi-
gate this possible association and find factors at the time of
diagnosis that were predictive of relapse, and differentiate
their prognostic relevance on the basis of the type of
childhood vasculitis.Methods
Patients
We retrospectively reviewed the charts of vasculitis
patients (onset age <18 years) who were admitted to the
Pediatric Rheumatology Ward of the National Taiwan
University Hospital, a tertiary referral center, from
December 1997 to December 2007, and who satisfied the
1990 American College of Rheumatology (ACR) criteria
based predominately on clinical findings and/or the Chapel
Hill Consensus conference (CHCC),3 which is based on
pathologic criteria for vasculitis. Urticaria vasculitis
patients were diagnosed by skin biopsy results, and the
diagnosis of infection associated vasculitis was dependent
on pathogen culture results or serologic reports. All
patients were ethnic Chinese. The demographics, clinical
features, diagnostic evaluations and outcomes of the
patients were recorded. Patients were excluded from the
Table 1 Classification of vasculitis
Class Name Pathophysiology Characteristics Associated disease
Large-vessel vasculitis Giant cell arteritis Granulomatous inflammation Most common over 50 years old Associated with polymyalgia
rheumatica
Takayasu arteritis Granulomatous inflammation Third-most common form of childhood
vasculitis
Associated with connective tissue,
autoimmune, endocrine
Pulseless disease
Medium-vessel vasculitis Kawasaki disease Vasculitis of coronary arteries,
aorta and veins may be
involved
Occurs usually in children Associated with mucocutaneous
lymph node syndromePotential aneurysm formation
The clinical features of fever persisting for
at least 5 days and plus the presence of at
least four principal features: exanthem,
conjunctival injection without exudate,
changes in extremities (erythema or
edema), changes in lip and oral cavity, and
cervical lymphadenopathy(> 1.5 cm
diameter), usually unilateral
Rheumatoid vasculitis Distal, symmetric polyneuropathy
Occurs in patients who have longstanding
rheumatoid arthritis
Angiitis of central nervous
system
Repeat angiogram after 4e6 weeks Evident on MRI/histopathology
Small-vessel vasculitis Henoch-Scho¨nlein purpura Necrotizing inflammation,
IgA-dominant immune deposits
Most common vasculitis in children Associated with arthralgias or
arthritisInvolves skin, gut, and glomeruli
Palpable purpura
Hypersensitivity vasculitis
(urticaria vasculitis)
Necrotizing inflammation Involves skin, joints Associated with connective tissue
diseases, autoimmune disorders,
viral hepatitis, or as a
paraneoplastic syndrome
Leukocytoclastic 40% of these patients have angioedema
which tends to be painful or burnSmall- to medium-vessel
Wegener’s granulomatosis Granulomatous inflammation Equal in men and women Necrotizing glomerulonephritis
common
Necrotizing inflammation Occurs in any age, but most cases occur in
adults
cANCA positive
Strawberry gums are a classic sign
ChurgeStrauss syndrome Granulomatous or necrotizing
inflammation (or both)
Upper respiratory tract, lungs, heart,
peripheral nerves
pANCA positive
Asthma history
ANCA Z antineutrophil cytoplasmic antibody; IgA Z immunoglobulin A; MRI Z magnetic resonance imaging.
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Table 2 Types of unspecific vasculitis
Case Type Age
(y)/
gender
Clinical
presentation
WBC
(/mL)
Platelets
(103/mL)
Neutrophils
(/mL)
Lymphocytes
(/mL)
CRP
(mg/dL)
ANA C3/C4
(mg/dL)
Others
I CSS 14/M Asthma, sinusitis 8740 272 7307 1101 5.82 1:160 164/38 Eos: 25.5%
IgE: 1822Pleural effusion
Mononeuritis
multiplex
II HD 4/F Fever 2860 32 744 829 4.33 1:40 107/21 Biopsy: granulocytes
in a perivascular
location Eos: 23%
Purpura
Rash
Medication at
disease onset
III DIV 6/F Purpura 3040 269 1003 1368 3.97 N/A N/A N/A
Arthralgia
ALL under
MTX control**
IV DIV 16/F Purpura 7220 226 4282 2137 3.67 1:40 N/A N/A
Arthralgia
V LV 11/F Chronic, recurrent
ulcers over
bilateral lower
extremities
4820 301 2612 1711 0.05 1:40 124/24 Biopsy: intraluminal
thrombosis
VI LV 14/F Progressive
erythematous
change and
ulceration over
bilateral leg
7790 169 2392 4417 0.03 1:40 N/A Biopsy: intraluminal
thrombosis
Purpura
VII TA 6/M Dyspnea 16,700 293 13,410 1987 5.54 N/A N/A Arteriogram
abnormality in
descending arteries,
left renal artery
Orthopnea
Upper
extremities
weakness
Subclavian steal
phenomenon
VIII VGI 10/F Abdominal pain 6720 260 3508 2822 0.07 1:40 133/19 Echo: normal
Weight loss
IX VGI 9/M Abdominal pain 10,450 202 5998 3459 4.92 1:40 N/A Echo: normal
Duodenal ulcer
Bloody stools
X UV 13/F Purpura, arthritis 8740 272 7307 1101 5.82 1:2560 N/A EBNA(þ) RF:1:5120
(continued on next page)
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26 M.-C. Teng et al.study if they were transferred from another hospital or
clinic without a description of the initial presentation or
laboratory results.
Diagnostic evaluation and follow-up
We recorded the diagnostic evaluation results at the time
of vasculitis diagnosis and during vasculitis flares. A relapse
was defined as the recurrence of clinical signs/symptoms or
the occurrence of new symptoms after an initial remission,
requiring the resumption of immunosuppressive therapy or
an increased dose. Diagnostic evaluation included complete
blood cell and differential cell counts, urinalysis, C-reac-
tive protein (CRP), antinuclear antibody, anti-dsDNA anti-
body, serum C3 and C4 levels, erythrocyte sedimentation
rate (ESR), antiphospholipid antibody (APA), and anti-
cardiolipin antibody (ACA). APAs were assayed using
an IMUCLONE aPL immunoglobulin (Ig) G enzyme-linked
immunosorbent assay (ELISA) kit (American Diagnostica,
Stamford CT., US) ACAs were assayed using AUTOZYME ACL
anticardiolipin IgG and IgM sandwich immunoassays (Cam-
bridge Life Sciences Ltd., Cambridgeshire, UK). Hematuria
was defined as the excretion of more than ten red blood
cells per high-power field in a centrifuged urine specimen
and/or urine dipstick test OB S one plus.
We reviewed the clinical charts for any clinical or
laboratory signs of remission or relapse at every visit and
recorded the time from disease onset to diagnosis, and
from diagnosis to first relapse.Statistical analysis
Data with a normal distribution were expressed as the
mean  SD, and non-normally distributed data were
expressed as the median (range). Between-group differ-
ences in categorical variables were examined using Fisher’s
exact test or the Chi-square test. For continuous data,
a Student t test or analysis of variance (ANOVA) was
employed. The Mann-Whitney U-test was used in non-
normally distributed data. To investigate the prognostic
significance of each demographic, clinical, and laboratory
characteristic, we computed the relapse in the study pop-
ulation as a whole, using logistic regression analysis, with
the time at risk starting from the time of the first remission
in the case of the prognostic indicators of relapse (the
outcome being the time to relapse after having censored
the follow-up for the vasculitic process). Additionally, we
performed the same tests after adjusting for the type of
vasculitis. Statistical significance was defined as p < 0.05.
Multivariate analysis was performed to investigate the
relationship between different types of vasculitis with
adjustments for sex and age. We also verified whether the
prognostic significance of each variable differed in relation
to the type of vasculitis by applying the likelihood ratio
test to the interaction term between each prognostic
indicator and the variable indicating the type of vasculitis.
The variables were entered by the enter variable selection
method. Using a stepwise backward elimination procedure,
we selected the variables that predicted the outcome with
a p value less than 0.05 by the Wald test. No interaction
term was included. All of the multiple regression models
were refitted after inclusion of the type of vasculitis, which
Table 3 Distribution of the vasculitis patients
HSP CNS
vasculitis
Urticaria
vasculitis
VAAD Infection
vasculitis
Unspecific
vasculitis
Cases 124 8 3 6 4 12
Age (y) 6.4  3.2 8.6  3.4 6.0  4.6 9.3  6.9 6.0  5.6 10.5  3.7
Gender
Male 74 (59.7) 0 2 (66.7) 3 (50) 1 (25) 3 (25)
Female 50 (40.3) 8 (100) 1 (33.3) 3 (50) 3 (75) 9 (75)
Skin involvement 106 (85.5) 0 3 (100) 4 (66.7) 4 (100) 9 (75)
Kidney involvement
Isolated urinary abnormalities 28 (22.6) 0 0 0 0 1 (8.3)
Impaired renal function 19 (15.3) 0 0 1 (16.7) 0 1 (8.3)
Categorical variables are shown as number (%) and continuous variables as mean values  SD. Isolated urinary abnormalities were
defined as the excretion of more than 10 red blood cells and/or white blood cells per high-power field in a centrifuged urine specimen
and/or urine dipstick test OB/proteinS one plus. Impaired renal function was defined as hematuria associated with at least two of the
following: increased serum urea and creatinine levels, hypertension, and oliguria or massive proteinuria (>40 mg/m2/h), hypo-
albuminemia (<2.5 g/dL) and edema.
CNS Z central nervous system; HSP Z Henoch-Scho¨nlein purpura; VAAD Z vasculitis associated with autoimmune disease.
Childhood vasculitis 27could potentially behave as a strong confounder in the
relationship between each predictor and the outcome. All
statistical analyses were computed using SPSS version 15.0
(SPSS Inc., Chicago, IL, USA).
Results
Distribution of vasculitis
According to the size of the predominant blood vessels
involved, there were three types of vasculitis involved: (1)
predominantly large-vessel vasculitides, including Takayasu
arteritis and giant cell arteritis; (2) predominantly medium-
vessel vasculitides, including classic polyarteritis nodosa,
cutaneous polyarteritis nodosa, rheumatoid vasculitis,
Kawasaki disease, and primary angiitis of the central
nervous system; and (3) predominantly small-vessel vascu-
litides, which contained three subtypes: (a) immune-
complex mediated, including cutaneous leukocytoclastic
angiitis (hypersensitivity vasculitis), HenocheScho¨nlein
purpura and urticarial vasculitis; (b) antineutrophil cyto-
plasmic antibody (ANCA)-associated disorders, including
Wegener’s granulomatosis, microscopic polyangiitis,Figure 1. Demographics of Henoch-Scho¨nlein purpura.ChurgeStrauss syndrome; and (c) miscellaneous small-
vessel vasculitides, including connective tissue disorders,
paraneoplastic diseases, infection, and inflammatory bowel
disease.Patient characteristics
A total of 508 vasculitis patients were included in this
study: 351 (69%) with Kawasaki disease, 124 (24%) with HSP,
eight (2%) with central nervous system (CNS) vasculitis,
three (1%) with urticaria vasculitis, six (1%) with vasculitis
associated with autoimmune disease (including three with
systemic lupus erythematosus (SLE), two with juvenile
rheumatoid arthritis (JRA), and one with juvenile derma-
tomyositis (JDM), four (1%) with infection vasculitis, and 12
(2%) with unspecific vasculitis (including two with drug-
induced vasculitis, two with gastrointestinal vasculitis, one
with ChurgeStrauss syndrome, one with Takayasu disease,
two with livedoid vasculitis, one with hypersensitivity
vasculitis, and the remaining three with unspecific vascu-
litis) (Table 2). There were 212 (42%) female and 296 (58%)
male patients. The mean ages at onset of different types
of vasculitis are shown in Table 3. HSP occurred mostFigure 2. Demographics of Kawasaki disease.
Table 4 Different clinical features between patients less than 1 year old and older than 1 year old in Kawasaki disease
1 year old 1 year old Total p value
Skin rash 86/109 (78.9) 196/242 (81.0) 282/351 (80.3) NS
Conjunctivitis 92/109 (84.4) 197/242 (81.4) 289/351 (82.3) NS
Lymphadenopathy 40/109 (36.7) 151/242 (62.4) 191/351 (54.4) 0.001
BCG scar erythema 50/109 (45.9) 39/242 (16.1) 89/351 (25.4) < 0.001
Desquamation 55/109 (50.5) 98/242 (40.5) 153/351 (43.6) NS
Oral symptoms 74/109 (68.2) 178/242 (73.6) 252/351 (71.8) NS
Dilated CA 52/109 (47.7) 76/242 (31.4) 128/351 (36.5) 0.027
Pyuria 39/109 (35.8) 47/242 (19.4) 86/351 (24.5) NS
GI symptoms 20/109 (18.3) 49/242 (20.2) 69/351 (19.7) NS
Categorical variables are shown as number (%).
BCG Z Bacille Calmette-Gue´rin; CA Z coronary artery; GI Z gastrointestinal; NS Z nonsignificance.
28 M.-C. Teng et al.frequently at a mean age of 5e7 years10 (Fig. 1), and
Kawasaki disease most frequently at a mean age of less
than 2 years (Fig. 2). The most common type of vasculitis
was HSP in outpatient clinics and most admissions were as
a result of Kawasaki disease (69%). Interestingly all cases
with CNS vasculitis were female. Renal involvement was
more common in HSP patients compared with other types of
vasculitis (Table 3). The male:female ratio found in our HSP
group (1.00:0.72) was comparable to those of previous
reports.4 Skin rashes were seen as a first manifestation in
408/508 cases (80.3%). This finding was again comparable
with earlier studies.1,5,6 Gastrointestinal (GI) symptoms and
signs preceded and/or were combined with the typical rash
for a period of days in 49/124 (39.5%) of the patients. The
most common complaint of GI involvement was abdominal
pain, often associated with vomiting.7,8 Joint involvement
was noted in 31/124 (25%) of patients and characterized by
warmth, tenderness and swelling of the joints, particularly
the large joints (specifically the ankles and knees). Joint
involvement left no permanent deformities.9 Interestingly,
we found that Bacille Calmette-Gue´rin (BCG) scar erythema
and dilated coronary arteries were more significantly found
in the patients aged less than 1 year who had Kawasaki
disease, and lymphadenopathy was more prominent in the
patients who were older than 1 year (Table 4). Thrombo-
cytosis was more obvious in those who had coronary dila-
tation in Kawasaki disease (Table 5).
Prognostic factors for relapse
In terms of clinical features and laboratory indicators, joint
involvement tended to relapse less frequently than theTable 5 Association between laboratory results and coronary a
With CAD
White blood cells 17,046.58  6593.65
Platelets 436,530  202,239
Neutrophils 10,662.14  5885.15
Lymphocytes 4527.14  2629.79
C-reactive protein (mg/dL) 8.75  5.20
Categorical variables are shown as number (%) and continuous variab
CAD Z coronary artery dilatation; NS Z nonsignificance.others, although the difference was not statistically
significant (pZ 0.058), whereas kidney disease was related
to a higher risk (p Z 0.000). Skin involvement (which was
not observed in CNS vasculitis patients) appeared to have
no effect on the prognosis of HSP (p Z 0.735). Multiple
regression analysis showed that renal involvement was an
independent evaluation factor for relapse or disease
activity in the HSP population. A decreased lymphocyte
count and CRP level were prominent in HSP patients,
especially compared with urticaria vasculitis. Thrombocy-
topenia was significant in vasculitis associated with auto-
immune disease (VAAD) patients compared to HSP patients.
Other laboratory data [white blood cells (WBC), neutro-
phils] were not significantly different between HSP and
other types (Table 6). The hematuria group of HSP patients
was more likely to experience recurrence than the non-
hematuria group (Table 7). Kawasaki disease recurred in
1.5% of all cases, and occurred most frequently in the
summer and least frequently in the winter. Huang et al11
reported that coronary artery aneurysms occurred in 7.2%
of all Kawasaki disease cases, and we found coronary artery
dilatation in up to 36.5% of cases (128/351).
Discussion
The mechanism involved in the pathogenesis of vasculitis is
still not well understood; however several lines of evidence
suggest that immunological factors, including immune
complexes might be implicated. In HSP patients, renal
involvement, an important prognostic factor in long-term
follow-up, is seen in only one-fifth of the patients.12
Nephritis occurs in 15e50% of children with HSP,12,13 andrtery dilatation in Kawasaki disease
Without CAD p value
12,661.35  4937.18 NS
327,600  115,683 0.002
7701.12  4052.31 NS
3602.25  2483.80 NS
6.35  4.70 0.051
les as mean values  S.D.
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Childhood vasculitis 29a substantial proportion of the patients show a delay of
weeks or months in the onset of renal involvement.
Fortunately, less than 1% of those with kidney involvement
progress to end-stage renal disease.10 Hematuria has been
reported to be a common initial manifestation of renal
disease, which is similar to our findings (28/124, 22.6%).12
An increased recurrence rate in the HSP patients with
early hematuria, as seen in our study, may easily trigger
another episode, possibly because of immune complexes
(IgA)14; however the role of complement activation is
controversial. The etiology of HSP is unknown, but often
follows an upper respiratory tract infection. Kidney disease
in combination with the involvement of other systems such
as cerebral and/or liver involvement is the most relevant
predictor of a poor prognosis in primary small-vessel
vasculitides.15 Other clinical manifestations such as
edema, gastrointestinal findings and recurrence rate in our
study were similar to previous reports,16 but joint mani-
festations were observed less frequently. There was
a significant relationship between renal and joint mani-
festations in contrast to the findings of Mir et al.17
Of all patients presenting with chronic urticaria, less
than 20% have urticarial vasculitis.18 Urticarial vasculitis is
a form of small- to medium-vessel vasculitis that presents
with urticarial wheals. Up to 40% of these patients have
angioedema, which persists for 24e72 hours and tends to
be painful or with a burning sensation, lasting for several
days, and healing with dyspigmentation or purpura.
Systemic symptoms are not uncommon and diagnosis is
usually made by histopathologic analysis.18,19 In our study,
we found an increase in CRP levels and lymphocyte
predominance in most of the urticarial vasculitis patients.
About 22% of all cases of cutaneous vasculitis are associ-
ated with infection,2 and it is likely that there is a common
morphologic endpoint of several pathways, including
immune complex formation, alternate pathways of
complement activation, and endotoxin-mediated expression
of vascular adhesion molecules.1,19
About 12% of cutaneous vasculitis cases are associated
with an autoimmune disease, and an enhanced expression
of vascular adhesion molecules attracting and activating
neutrophils is suspected to play a role in the pathogenesis
of VAAD.20 Thrombocytopenia was more prominent among
the VAAD patients in our study than any other group
because of their underlying diseases.
In Kawasaki disease, there is little information showing
the risk of coronary artery dilatation between different age
groups. We found that the prevalence of coronary artery
disease (CAD) in Kawasaki disease was more prominent in
those patients who were younger than 1 year of age and had
an initial laboratory result of thrombocytosis. So, the age
group should be considered during treatment choice. The
BCG scar erythematous changewas considered in the clinical
manifestation, and the relationship between BCG scar and
genome type was discussed by Tsai et al,21 but they did not
discuss the relationship between BCG scar and age group.21
Therefore, in this study we looked for factors that could
affect the clinical presentation in different age groups.
In conclusion, this study showed that vasculitis disease
activity and prognosis were associated with initial labora-
tory results and clinical manifestations at the first visit to
our clinic, and may provide future outcome and treatment
Table 7 Relationship between recurrence and hematuria in HenocheScho¨nlein purpura patients
Recurrenta Nonrecurrent p value
Urine OB 15/20 (75%) 13/104 (13%) <0.001
Stool OB 5/20 (25%) 22/104 (21%) 0.633
White blood cells 11,044.74  4203.65 12,186.63  3414.60 0.199
Platelets 336,470  108,148 356,990  99,010 0.414
Neutrophils 7915.18  4095.09 8369.96  3474.94 0.611
Lymphocytes 2365.66  1059.80 2918.20  1273.43 0.078
C-reactive protein 0.500 (0.00e10.01) 0.430 (0.00e14.33) 0.580
Arthralgia 1/20 (5%) 30/104 (29%) 0.052
Skin 18/20 (90%) 88/104 (85%) 0.735
Gastrointestinal symptoms 6/20 (30%) 43/104 (41%) 0.342
a Recurrence within 3 months from first remission.
30 M.-C. Teng et al.considerations for patients with different kinds of vascu-
litis. As only a few cases of rare types of vasculitis were
found in our investigation, further studies with larger
numbers of patients are warranted to validate our findings.References
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